Essential Questions for Designing an Effective Feasibility Questionnaire

Understanding the Role of Feasibility Questionnaires

Before selecting sites and investigators, sponsors and CROs must carefully evaluate a site’s ability to successfully execute a clinical trial. A feasibility questionnaire is one of the most important tools for this assessment. These documents collect structured information about a site’s resources, patient pool, regulatory experience, and infrastructure readiness. Regulatory agencies such as the FDA, EMA, and national authorities expect sponsors to document feasibility efforts as part of Good Clinical Practice (GCP) compliance. Without a robust feasibility process, sponsors risk delays, under-enrollment, and inspection findings during trial audits.

Feasibility questionnaires typically cover domains such as:

• Patient recruitment and retention potential
• Principal Investigator (PI) and sub-investigator experience
• Site infrastructure, including equipment and labs
• Previous performance in similar therapeutic areas
• Local regulatory and ethics committee processes

For example, in oncology studies, questionnaires often probe whether the site has access to pathology labs capable of immunohistochemistry testing, or whether genetic testing partnerships exist. In infectious disease studies, questions may focus on availability of biosafety level facilities. Thus, while core domains remain consistent, therapeutic area–specific tailoring is essential.

Critical Patient-Related Questions

Patient recruitment is one of the most common barriers to timely trial completion. Regulators, including the European Medicines Agency (EMA), emphasize that feasibility assessments should be realistic and data-driven. A questionnaire must therefore ask targeted questions about patient populations. Examples include:

Incorporating epidemiological data strengthens these questions. For example, if a site estimates 300 eligible patients annually but national disease burden data suggests fewer than 50 cases in the region, this discrepancy raises concerns about overestimation. Sponsors should cross-check questionnaire responses with external databases such as ClinicalTrials.gov to validate feasibility claims against trial recruitment histories.

Questions on Investigator and Staff Experience

A site’s human resources are equally critical. Regulators often highlight inadequate investigator oversight as a frequent finding in inspections. Questionnaires should evaluate whether the PI and supporting staff have the necessary experience. Key questions include:

• How many clinical trials has the PI conducted in the past five years, and in which therapeutic areas?
• Has the PI received any regulatory inspection findings related to GCP?
• What is the average turnover rate of study coordinators and research nurses?
• What GCP training and certification do staff currently hold?

For example, a PI with ten oncology trials completed but with multiple FDA Form 483 citations may be a higher risk compared to a less experienced PI with a clean regulatory record. Feasibility questionnaires should capture such nuances.

Infrastructure and Technology Questions

Infrastructure capability directly influences trial quality. For complex trials requiring bioanalytical testing, imaging, or cold-chain management, questionnaires must go beyond basic facilities inquiries. Sample questions include:

• Does the site have validated -80°C freezers with continuous temperature monitoring?
• Are backup power systems in place to safeguard sample integrity?
• Is the site equipped with validated software for electronic data capture (EDC)?
• Are laboratory instruments calibrated according to international standards (e.g., ISO 15189)?

Some questionnaires include sample validation parameters such as:

These details help sponsors differentiate between sites that claim readiness and those that are genuinely prepared for trial operations.

Regulatory and Ethics Questions

Finally, feasibility questionnaires must assess local regulatory and ethics environments. Delays in IRB/EC approvals are a common reason for missed trial timelines. Essential questions include:

• What is the average IRB/EC review timeline for clinical trials at your institution?
• Do you have prior experience submitting to regulatory authorities such as FDA, EMA, CDSCO, or PMDA?
• Are there institutional policies restricting enrollment of vulnerable populations?

For example, if a site reports an average of 45 days for ethics approvals, sponsors can plan activation timelines accordingly. Sites with extended timelines (e.g., >90 days) may not be suitable for fast-track studies.

Transition to Next Considerations

The above domains—patient recruitment, investigator experience, infrastructure, and regulatory landscape—form the backbone of feasibility questionnaires. However, sponsors must also evaluate validation of responses, data reliability, and strategies to prevent overpromising. These aspects will be explored in Part 2, with focus on case studies, pitfalls, and best practices for robust feasibility planning.

Validating Feasibility Questionnaire Responses

Feasibility questionnaires are only useful if responses are accurate. Regulators and sponsors increasingly emphasize data verification as part of trial oversight. Sponsors must apply validation strategies to ensure that sites are not inflating capabilities or patient pools to secure trial participation.

One approach is to cross-verify patient pool estimates with hospital records, referral databases, or national disease registries. For example, if a site reports 500 annual cases of Type 2 diabetes, but regional public health data suggests only 300 cases, the sponsor should investigate. Similarly, sponsors should request anonymized patient counts or ICD-10 code reports to substantiate claims.

Case Study: Inflated Patient Recruitment Claims

A multinational sponsor faced delays in an oncology trial when three sites overestimated recruitment potential. While questionnaires projected 50 patients per site annually, actual enrollment was less than 10. Upon review, it was found that sites included patients outside inclusion criteria. This case underscores the importance of rigorous validation, including review of electronic health records (EHRs) and prior recruitment histories from registries such as ISRCTN Registry.

Common Pitfalls in Questionnaire Design

Despite best intentions, poorly designed questionnaires often result in incomplete or misleading data. Common pitfalls include:

• Overly generic questions that do not capture therapeutic-specific nuances
• Yes/No questions without quantitative context (e.g., “Do you have lab facilities?” instead of “How many calibrated centrifuges are available?”)
• Failure to include data validation fields or request supporting documentation
• Excessive questionnaire length leading to incomplete responses

To avoid these issues, sponsors should pilot-test questionnaires with selected sites and adjust based on feedback. Regulatory authorities also recommend focusing on essential questions that directly impact trial feasibility, rather than exhaustive lists that burden sites unnecessarily.

Best Practices for Effective Questionnaires

Effective feasibility questionnaires balance comprehensiveness with clarity. Best practices include:

• Tailoring questionnaires by therapeutic area (oncology, cardiology, infectious disease)
• Using a mix of quantitative and qualitative questions
• Integrating electronic platforms to streamline completion and analysis
• Embedding mandatory data validation checks (e.g., requiring supporting documentation uploads)

Some sponsors now deploy digital feasibility tools integrated with Clinical Trial Management Systems (CTMS). These allow automated scoring, comparison across sites, and identification of red flags such as inconsistent patient data. For example, an AI-enabled feasibility tool might score sites based on patient pool adequacy, infrastructure readiness, and regulatory history, generating a composite feasibility index for decision-making.

Sample Feasibility Scoring Framework

This weighted approach ensures objective decision-making while allowing customization for specific trial needs. For instance, in rare disease studies with small populations, patient recruitment weight might increase to 60%.

Conclusion

Feasibility questionnaires are a cornerstone of site selection and clinical trial planning. By including targeted questions on patients, investigators, infrastructure, and regulatory environment—and by validating responses through data cross-checks—sponsors can mitigate risks of underperformance and regulatory non-compliance. Effective design not only accelerates trial start-up but also strengthens inspection readiness by demonstrating a structured feasibility process.

Adapting Feasibility Tools to Specific Therapeutic Areas in Clinical Trials

Why Customization Matters in Feasibility Assessments

While feasibility questionnaires are a standard component of clinical trial planning, a “one-size-fits-all” approach often results in incomplete or misleading data. Different therapeutic areas present unique operational, regulatory, and recruitment challenges. Therefore, it is essential to adapt feasibility tools based on the specific clinical, procedural, and patient population characteristics of each therapeutic indication.

Regulatory agencies like the FDA and EMA expect feasibility efforts to align with study-specific complexities. For example, a Phase III oncology trial will have very different infrastructure and recruitment requirements compared to a vaccine study or a dermatology trial. Customization ensures that the sponsor gathers high-fidelity, indication-specific data, which reduces trial delays, improves protocol adherence, and enhances inspection readiness.

In this tutorial, we explore how sponsors and CROs can develop and deploy feasibility tools tailored to therapeutic areas including oncology, cardiology, infectious diseases, CNS disorders, and rare diseases.

Key Variables Differentiating Therapeutic Areas

Each therapeutic area involves unique variables that influence trial feasibility, including:

• Diagnostic criteria and screening processes
• Specialized equipment and lab tests
• Patient population size and disease prevalence
• Eligibility complexity and inclusion/exclusion criteria
• Site specialization and investigator qualifications

For example, an oncology trial may require immunohistochemistry, genetic sequencing, and radiologic assessments, while a vaccine trial may emphasize storage conditions for biologics and capacity for large-scale subject screening. Failing to account for these differences can lead to underperformance and protocol deviations.

Customizing Feasibility Tools in Oncology Trials

Oncology trials are often complex, with multiple arms, biomarker-based eligibility, and long treatment durations. Therefore, feasibility tools must address:

• Availability of tissue samples for biomarker testing
• Access to imaging facilities for RECIST-based assessments
• Experience in handling cytotoxic agents and managing SAE reporting
• Supportive care services like transfusion, nutrition, and palliative care

Below is a sample customization framework for oncology feasibility:

Oncology sites must also demonstrate access to multidisciplinary tumor boards, availability of radiology archiving systems, and electronic SAE tracking tools such as Argus Safety. To cross-reference recruitment and prior site experience, sponsors may consult the EU Clinical Trials Register.

Adapting Feasibility for Cardiovascular Trials

Cardiology studies may involve device implantation, ECG monitoring, and stress testing. In such cases, feasibility tools must capture:

• Availability of validated ECG and echocardiogram equipment
• GCP training in cardiovascular endpoints (e.g., MACE criteria)
• Presence of a catheterization lab or interventional cardiologist
• Patient adherence history in hypertension or dyslipidemia trials

Sample values might include:

• Validated ECG machine model: GE MAC 5500
• Calibration certificate date: June 2025
• Cardiology sub-investigator GCP completion: March 2024

Moreover, cardiology trials may need precise documentation of concomitant medications and lifestyle interventions. Questionnaires must be adapted to capture these site competencies.

Feasibility Tools for Infectious Disease Trials

Infectious disease trials—especially in vaccines or antimicrobial resistance studies—require a different set of site capabilities. Sponsors must customize feasibility questionnaires to capture:

• Cold-chain infrastructure for biologics (2–8°C and -20°C storage)
• Experience with biosafety level (BSL-2 or BSL-3) laboratory handling
• Regulatory familiarity with expedited review processes (e.g., EUA)
• Access to outbreak-prone communities or travel clinics

Feasibility templates for such trials often include verification of:

Sites that have participated in past epidemic response trials (e.g., COVID-19, H1N1) often score higher in feasibility assessments due to institutional readiness and protocol familiarity.

Feasibility Considerations in CNS Trials

CNS trials for indications like Alzheimer’s, Parkinson’s, or depression bring unique recruitment and assessment challenges. Key customization points include:

• Site capability for neurocognitive assessments (e.g., MMSE, MoCA)
• Investigator training in psychiatric or neurologic scales
• Caregiver consent handling for dementia patients
• Experience with long-term follow-up visits (≥12 months)

Example question: “Is your site trained in administering ADAS-Cog or CDR-SB assessments for Alzheimer’s patients?”

Feasibility tools must also factor in patient adherence barriers, comorbidities, and ability to comply with imaging and lab visit schedules. CNS studies often suffer from high dropout rates, so feasibility assessments should include questions on patient retention strategies.

Special Feasibility Approaches in Rare Disease Trials

Rare disease studies are constrained by extremely small patient populations. Feasibility tools in this context must go beyond traditional metrics and emphasize:

• Site access to patient registries or genetic databases
• Partnerships with advocacy groups or KOL networks
• Willingness to enroll non-local patients (e.g., travel support programs)
• Experience in adaptive trial designs and expanded access protocols

Due to ultra-orphan populations, sponsors may consider virtual or decentralized feasibility approaches, integrating telemedicine and remote monitoring tools. Additionally, feasibility questionnaires should include sections on protocol flexibility and site logistics for rare disease patients traveling long distances.

Best Practices for Implementing Customized Tools

To deploy customized feasibility tools effectively:

• Develop therapeutic area-specific templates reviewed by KOLs
• Pre-fill public domain data (e.g., IRB timelines) to reduce site burden
• Digitize questionnaires using secure platforms integrated with CTMS
• Score site responses using indication-weighted algorithms
• Train feasibility teams on therapeutic-specific nuances

Some organizations maintain a Feasibility SOP that includes annexures for oncology, cardiology, etc., ensuring consistency while allowing adaptation. For sponsors working with multiple CROs, standardizing customized tools via cross-functional working groups is recommended.

Conclusion

Feasibility tool customization is a regulatory, scientific, and operational imperative. Generic questionnaires can no longer capture the complexity of modern trials across diverse therapeutic areas. By developing indication-specific tools—grounded in real-world data, infrastructure requirements, and investigator qualifications—sponsors can enhance patient recruitment, ensure compliance, and minimize protocol deviations. With global trials becoming more complex, therapeutic customization of feasibility tools is essential for success in today’s regulatory environment.

Designing Feasibility Questionnaires Using Historical Site Data

The Importance of Historical Site Data in Feasibility Planning

Feasibility questionnaires are foundational tools in clinical trial planning. They help sponsors and CROs identify and select high-performing sites based on several factors like patient pool, investigator experience, infrastructure, and regulatory track record. However, when these questionnaires are designed without historical context, they can result in overly optimistic or inaccurate site responses. That’s where leveraging historical site data becomes critical.

Historical site data includes past enrollment rates, protocol deviation frequencies, screen failure rates, regulatory inspection outcomes, and adherence to visit schedules. Sponsors that fail to incorporate this data often face recruitment delays, budget overruns, and poor site compliance. Regulatory bodies including the FDA, EMA, and MHRA emphasize the use of evidence-based feasibility strategies during sponsor inspections.

In this article, we explore how to use historical site data to design smarter, more predictive feasibility questionnaires that improve site selection and study startup efficiency.

Types of Historical Data Relevant to Questionnaire Design

Historical site data spans multiple domains. The most useful categories include:

• Enrollment History: Number of subjects enrolled in similar trials within a specific timeframe
• Protocol Adherence: Frequency of deviations and their root causes
• Screen Failure Rates: Percentage of screened patients not meeting inclusion criteria
• Site Activation Timelines: Average time from contract finalization to first patient in (FPI)
• Regulatory Inspection Outcomes: FDA 483 observations, MHRA findings, or internal QA audits

Below is an example data summary from three sites in a cardiovascular trial:

From this table, it’s evident that Site A outperformed others in all key areas. Integrating this insight into a questionnaire helps to focus future feasibility assessments on parameters that matter.

Integrating Data into Feasibility Questionnaire Logic

Feasibility tools often consist of static checklists or self-reported site capabilities. When these are integrated with historical performance data, they become much more predictive. Here’s how historical data can enhance questionnaire sections:

• Recruitment Potential Section: Pre-fill enrollment numbers from past studies and ask the site to explain any changes
• Protocol Adherence Section: Highlight deviation patterns from previous trials and assess current mitigation measures
• Timeline Commitments: Use actual past activation data to validate new timeline estimates

For example, a dynamic form might display: “In your last three trials in this therapeutic area, your average enrollment was 20 patients over 6 months. What has changed to support your estimate of 60 patients in this protocol?”

This approach discourages over-promising and helps differentiate high-performing, realistic sites from aspirational responders.

Sources of Historical Site Data

Historical site data can be gathered from several internal and public sources:

• Clinical Trial Management Systems (CTMS): Capture site-level metrics from previous studies
• Electronic Data Capture (EDC) Platforms: Document protocol adherence and visit windows
• Trial Registries: Data from Be Part of Research (NIHR) and other registries to validate enrollment timelines
• Quality Management Systems (QMS): Archive audit outcomes, CAPA timelines, and deviations

Sponsors that maintain a structured site master file with past feasibility, audit reports, and performance summaries can extract this data with minimal effort. It’s also beneficial to include CRO partner databases and publicly available performance scores (e.g., from the TransCelerate Shared Investigator Platform).

Feasibility Questionnaire Elements That Benefit from Data Integration

Not all parts of a feasibility questionnaire require historical data, but certain sections benefit significantly from it:

By designing forms with auto-filled historical fields, sponsors can reduce bias and increase transparency. Some tools even allow scoring systems based on prior performance benchmarks.

Case Study: Data-Driven Feasibility Yields Better Enrollment

In a 2023 Phase II neurology study, the sponsor used historical site performance data to filter out low-recruiting sites from a previous epilepsy trial. By incorporating metrics such as “patients enrolled per FTE” and “visit adherence rate,” they excluded 30% of sites that had previously delayed timelines. The remaining sites achieved 95% of the recruitment target three months ahead of schedule.

This outcome illustrates how applying historical metrics during feasibility tool design directly impacts enrollment, cost, and data integrity.

Tools and Platforms That Support Data-Driven Questionnaire Design

Sponsors can use various platforms to operationalize this approach:

• CTMS Platforms: Veeva Vault CTMS, Medidata RAVE
• Feasibility Tools: SiteIQ, Clinscape Feasibility Module
• Analytics Dashboards: Tableau, Power BI connected to CTMS/EDC sources
• Risk-Based Monitoring Tools: RBM dashboards that include performance trend lines

These systems allow sponsors to design adaptive questionnaires, conduct real-time validation of site claims, and score site responses against benchmarks.

Challenges and Considerations

Despite the advantages, there are challenges to using historical data:

• Data inconsistency across CROs and systems
• Lack of access to complete legacy data for global sites
• Privacy and data protection regulations (e.g., GDPR)
• Misinterpretation of context (e.g., poor performance due to protocol flaws, not site issues)

Therefore, sponsors must contextualize historical data and allow sites to provide explanations for deviations or poor performance. Data should be used to initiate dialogue, not penalize sites without cause.

Conclusion

Designing feasibility questionnaires using historical site data enables evidence-based site selection, reduces trial risk, and improves regulatory compliance. Sponsors should move away from static, self-reported surveys and adopt dynamic, data-informed tools that consider past performance. Platforms such as CTMS, QMS, and analytics dashboards can help integrate these insights into feasibility tools, creating a predictive framework for identifying high-performing, inspection-ready sites. In doing so, the industry takes a meaningful step toward smarter, faster, and more reliable clinical trial execution.

Frequent Mistakes to Avoid When Designing Feasibility Surveys

Why Survey Design Matters in Clinical Feasibility

Feasibility surveys are the first checkpoint in clinical trial execution. Sponsors, CROs, and clinical teams rely on these tools to determine which investigator sites are capable of enrolling, complying, and delivering high-quality data. However, flawed survey design can compromise this entire process—leading to site underperformance, protocol deviations, missed enrollment targets, and costly delays. Regulatory authorities like the FDA and EMA have highlighted the importance of accurate feasibility assessments in multiple inspection reports.

Designing an effective feasibility questionnaire is not just about gathering information—it’s about ensuring the **quality, clarity, and relevance** of the data collected. Poor design choices can introduce bias, reduce response rates, and provide misleading inputs, ultimately affecting trial success.

This article explores common pitfalls in feasibility survey design and provides corrective strategies to improve accuracy, efficiency, and regulatory alignment.

1. Over-Reliance on Generic Questionnaires

One of the most frequent mistakes is using generic, one-size-fits-all surveys across all therapeutic areas and trial phases. This ignores the unique requirements of different indications. For example, asking only “Do you have imaging capabilities?” in an oncology trial overlooks critical aspects like:

• Type of imaging (CT, MRI, PET)
• RECIST or iRECIST measurement familiarity
• Archiving and transfer compliance (DICOM format)

Similarly, a vaccine trial might need cold chain logistics and mass-screening capacity questions, which may be completely irrelevant to a rare disease gene therapy study. Lack of customization can cause misaligned expectations and downstream failures.

2. Ambiguous or Leading Questions

Vague phrasing leads to inconsistent interpretation and invalid data. For instance, asking “Can you enroll patients quickly?” is subjective. What qualifies as “quick” for one site may differ from another. Instead, a better version would be:

“How many patients fitting the protocol inclusion criteria did your site enroll in the last 12 months for similar Phase II studies?”

Leading questions also bias the respondent. “You have successfully conducted previous trials, correct?” might trigger social desirability bias. Neutral, fact-based phrasing is key.

3. Excessive Length and Complexity

Lengthy surveys with poor flow reduce completion rates and frustrate site staff. In multi-center trials, sites often have limited staff availability, especially during active study periods. Surveys that take over 45 minutes are less likely to be completed accurately. Issues include:

• Redundant questions across sections
• Poor section organization (e.g., mixing regulatory and infrastructure questions)
• Lack of autosave or ability to pause and resume digital forms

As a best practice, limit questionnaires to 25–30 well-structured questions for initial feasibility, followed by site-specific deep dives as needed. Use digital platforms that allow intuitive navigation and validation.

4. Lack of Data Validation or Documentation Fields

Another flaw is the absence of cross-checks or request for supporting documentation. For example, if a site claims it can enroll 100 patients over 6 months, sponsors should request either:

• Patient registry screenshots
• De-identified electronic health record reports
• Recruitment logs from similar studies

Without these, responses are based solely on memory or estimates, increasing risk of over-promising. Platforms should include fields for file uploads, comment boxes for clarification, and warning prompts for unusual entries.

5. Ignoring Historical Site Performance Data

Failing to consider a site’s previous trial history is a major oversight. Historical data helps contextualize feasibility answers and filter out consistently underperforming sites. For example:

Integrating such data-driven benchmarking within the survey design significantly improves reliability and transparency.

Transition to Solutions and Best Practices

Now that we’ve identified major pitfalls in feasibility survey design, the next part will offer regulatory-aligned solutions, practical templates, and technology integrations to improve the quality of your feasibility assessments.

6. Neglecting to Capture PI and Sub-Investigator Details

Many feasibility surveys focus primarily on site-level infrastructure while ignoring investigator qualifications. Yet, the PI’s past experience, availability, and regulatory track record are critical success factors. A well-designed survey should capture:

• Number of trials conducted in the last 5 years
• Therapeutic area alignment with the protocol
• GCP training validity and inspection history
• Ratio of PI to concurrent active trials

Neglecting to gather such details could lead to site activation delays due to regulatory rejection of PI credentials or unavailability.

7. Overlooking Regional and Regulatory Context

Global feasibility surveys often ignore country-specific regulations and operational limitations. For example:

• In India, the CDSCO has specific rules regarding ethics approvals and compensation
• In Japan, feasibility surveys must include PMDA-specific compliance sections
• In the EU, surveys must align with EU Clinical Trial Regulation (CTR) timelines and document requirements

Not including such country-specific sections can result in inaccurate site feasibility outcomes. For global trials, it’s critical to tailor questions by region or include branching logic that triggers local regulatory queries based on country selection.

8. No Mechanism to Capture Feasibility Risk Flags

A robust feasibility survey should include logic or scoring that auto-generates red flags based on site responses. For instance:

Response	Flag
PI is involved in 7 concurrent studies	Investigator overload
Site has no GCP training in last 3 years	Non-compliance risk
Startup timeline > 90 days	High activation risk

Such automated risk indicators help feasibility managers prioritize follow-ups and site visits.

9. Lack of Digital Integration and Data Traceability

Paper-based or email surveys still exist in some trials, resulting in data loss, miscommunication, and lack of audit trails. Regulatory inspectors, including from the FDA, expect version control, date/time stamps, and investigator signatures on feasibility forms.

Surveys should be integrated into platforms like Veeva CTMS, Clario Feasibility, or other compliant digital tools. This enables audit-ready documentation and seamless comparison across protocols and regions.

10. Ignoring Site Feedback for Continuous Improvement

Finally, many sponsors and CROs fail to review site feedback post-survey. Sites may provide comments such as:

• “Questions are repetitive or unclear”
• “Form is too long for busy clinics”
• “Unable to attach required documents easily”

Incorporating this feedback into subsequent versions ensures higher response rates, better data, and improved sponsor-site collaboration. Sponsors should conduct post-survey reviews or pilot testing to optimize forms continuously.

Best Practice Recommendations

• Limit initial surveys to 25–30 critical questions
• Use digital tools with conditional logic and data upload fields
• Benchmark recruitment estimates with historical performance
• Customize by therapeutic area and regulatory region
• Include risk scoring and auto-flagging mechanisms
• Maintain an audit-ready record with version control and timestamps

Tools like Clinscape, TrialHub, and Medidata can help structure and automate these best practices into scalable survey systems.

Conclusion

Feasibility surveys are the foundation of successful clinical trials. Yet, poor design introduces risk, waste, and non-compliance. Sponsors and CROs must recognize and avoid the common pitfalls outlined above—generic questions, ambiguous wording, missing validations, and absence of risk flagging. By adopting best practices, leveraging digital platforms, and integrating historical data, sponsors can build robust, regulatory-aligned feasibility tools that drive accurate site selection and successful trial execution.

How Digital Platforms Are Revolutionizing Clinical Trial Feasibility Collection

The Shift from Manual to Digital Feasibility Processes

Traditional feasibility collection in clinical trials involved paper-based questionnaires, spreadsheets, and email threads—an approach that was time-consuming, error-prone, and lacked standardization. As clinical trials have grown in complexity and scale, especially across multinational regions, digital platforms have become essential tools for collecting, analyzing, and managing feasibility data.

These platforms allow sponsors and CROs to efficiently gather site-specific information, automate validation, streamline global coordination, and ensure regulatory readiness. Whether it’s startup timelines, patient population details, or investigator qualifications, digital platforms are transforming how feasibility questionnaires are created, distributed, and analyzed.

In this tutorial, we explore how to leverage digital platforms for feasibility data collection, key platform features, real-world benefits, regulatory expectations, and the challenges of implementation in GxP environments.

Key Features of Digital Feasibility Platforms

Modern digital feasibility tools offer a variety of features designed to enhance data accuracy and usability. Some common capabilities include:

• Web-based, mobile-friendly questionnaires
• Conditional logic and branching paths based on responses
• Data validation checks with required fields
• Document upload capabilities (e.g., CVs, lab certifications)
• Pre-filled fields from CTMS or prior trial data
• Version control and audit trail logging
• Feasibility scoring algorithms
• Integration with CTMS and eTMF systems

For example, a site may receive a digital questionnaire that auto-fills their previous trial performance (e.g., 45 patients enrolled in a diabetes trial in 2022) and requests justification for a proposed higher recruitment rate in the current protocol. Such dynamic functionality reduces overestimation and improves data integrity.

Examples of Widely Used Digital Tools

Several platforms are now widely adopted in feasibility planning and site selection:

• Veeva Vault Study Startup: Offers feasibility tracking, site questionnaires, and document workflow
• Clario Site Feasibility: Provides centralized dashboards, automation, and metrics analytics
• TrialHub: Combines feasibility intelligence and real-world evidence data
• SiteIQ: Scores site responses using historical trial data benchmarks

These tools help eliminate manual communication, standardize site evaluation globally, and shorten trial start-up timelines by 30–50% in some cases. They also allow for early detection of red flags using built-in analytics.

Benefits of Digital Feasibility Collection

Using digital platforms brings significant advantages for sponsors, CROs, and sites:

• Speed: Centralized access accelerates survey completion and review
• Data Quality: Built-in validation ensures clean, usable responses
• Standardization: Uniform questionnaires across global regions
• Audit Readiness: Digital timestamps, versioning, and metadata tracking
• Remote Access: Enables decentralized feasibility from any location
• Integrated Analytics: Feasibility dashboards for real-time decision-making

For example, in a Phase III vaccine trial with 60 sites across Asia and Latin America, using a digital feasibility system reduced the questionnaire review cycle from 15 days to 5, and allowed site prioritization based on algorithmic scoring of patient pool, investigator experience, and previous performance.

Data Privacy and Regulatory Considerations

While digital tools enhance feasibility collection, sponsors must ensure GxP and data privacy compliance. Digital systems must meet:

• 21 CFR Part 11 electronic records/signature compliance (FDA)
• Annex 11 of EU GMP Guidelines (EMA)
• Data encryption and role-based access control
• GDPR for EU-based investigator and patient data

Audit trails are critical. Regulators expect systems to maintain metadata for each action, such as questionnaire issuance, completion, edits, and sign-offs. Failing to maintain a compliant system can lead to inspection findings. A strong vendor selection and validation process is necessary before deployment.

Workflow Example: End-to-End Feasibility Using Digital Platforms

A typical digital feasibility workflow includes:

1. Study team designs a therapeutic-area specific questionnaire on the platform
2. System pulls pre-existing site info (e.g., past enrollment metrics) from CTMS
3. Questionnaire distributed to selected sites with time-bound completion request
4. Sites respond, upload documentation, and e-sign digitally
5. Feasibility manager reviews auto-flagged responses (e.g., low patient pool, delayed start-up)
6. Data exported to dashboards and linked to selection scorecards
7. Selected sites proceed to contract negotiation and SIV scheduling

This automation replaces dozens of email threads, Excel sheets, and redundant document requests. It also ensures inspection-readiness at every step.

Integration with Other Clinical Systems

Digital feasibility tools do not operate in isolation. Leading platforms integrate with:

• Clinical Trial Management Systems (CTMS): Pull historical performance data
• Electronic Trial Master File (eTMF): Archive signed questionnaires and CVs
• eConsent and eCOA platforms: Evaluate site readiness for digital subject interfaces
• Analytics tools: Power BI, Tableau for site scoring dashboards

For instance, when a feasibility questionnaire flags a site’s lack of eConsent capability, that insight can be sent directly to the digital operations team to arrange supplemental training or support.

Challenges in Digital Adoption

Despite benefits, digital feasibility faces challenges:

• Site Resistance: Some smaller or academic sites may lack technical infrastructure
• Platform Training: Investigators and coordinators may need onboarding to navigate tools
• Vendor Oversight: CROs must ensure system validation and GxP compliance
• Localization: Multi-language support and regional question adaptations are often limited

To overcome these, sponsors should involve site staff in platform evaluation, provide helpdesk support, and conduct platform-specific SOP training during feasibility rollout.

Use Case: Oncology Trial Leveraging Digital Feasibility

In a recent multicenter Phase II oncology trial across Europe, a sponsor used a digital feasibility platform with built-in analytics. The tool analyzed previous enrollment history, site IRB timelines, and availability of certified imaging centers. Sites scoring below the threshold were excluded automatically. Results:

• Startup timeline reduced by 22%
• Protocol deviations dropped by 15%
• Enrollment met 100% target within projected window

The sponsor used integration with CTRI India and other global registries to cross-check recruitment histories—further validating questionnaire responses using historical performance data.

Conclusion

Digital platforms are no longer optional in modern clinical trial feasibility planning—they are critical. From automated data validation to centralized analytics and regulatory audit trails, these systems enable smarter, faster, and more compliant trial startup. Sponsors and CROs that adopt digital feasibility tools can reduce risk, cut costs, and improve site selection precision. As trials become increasingly global and decentralized, leveraging digital platforms is the cornerstone of operational excellence in clinical development.

Ensuring Regulatory Compliance During Clinical Feasibility Assessments

Introduction to Regulatory Oversight in Feasibility Planning

Feasibility assessments are not merely operational tools for site selection—they are regulatory expectations. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), along with other global authorities, expect sponsors and CROs to conduct structured and documented feasibility assessments as part of Good Clinical Practice (GCP) compliance. Feasibility questionnaires, data validation, and documentation must align with ICH E6(R2), which emphasizes risk-based trial planning and site qualification.

Failure to perform adequate feasibility assessments has been cited in multiple inspection reports. These findings often involve:

• Inadequate documentation of site capability assessments
• Inconsistent feasibility processes across countries or trials
• Overreliance on self-reported, unvalidated data
• Absence of feasibility SOPs or version control

In this tutorial, we cover how to design and execute feasibility assessments that are fully compliant with regulatory requirements. We include real-world examples, inspection citations, and tools to ensure documentation and process rigor.

Regulatory Frameworks Governing Feasibility

The following frameworks guide regulatory expectations around feasibility in clinical development:

• ICH E6(R2) GCP Guidelines: Requires sponsors to evaluate investigator and site suitability (Section 5.6 and 5.18)
• FDA Compliance Program Manual 7348.811: Recommends inspection of sponsor site selection criteria
• EMA GCP Inspectors Working Group Reflection Paper: Highlights deficiencies in feasibility documentation as a key inspection risk
• MHRA GCP Guide: Emphasizes robust feasibility as part of trial start-up planning

These guidelines stress not only the presence of a feasibility assessment but also its documentation, validation, and consistency across clinical programs.

Minimum Documentation Requirements

A regulatory-compliant feasibility package should include:

For example, if a site claims they can enroll 40 patients with a rare genetic disorder, the sponsor must retain justification such as regional disease prevalence reports, or prior enrollment records validated by registry data like Japan’s RCT Portal.

Common Regulatory Audit Findings

Below are real-world FDA and EMA audit observations related to feasibility:

• “The sponsor did not document the criteria used for selecting investigator sites.”
• “Feasibility assessments lacked supporting data to justify projected recruitment timelines.”
• “No evidence that sponsor reviewed investigator GCP training prior to site initiation.”
• “Feasibility SOP was outdated and inconsistently applied across regions.”

These findings not only delay trial progression but can result in critical or major inspection outcomes that require CAPA submission and re-inspection.

Role of Feasibility SOPs and Governance

Sponsors must implement and follow a standardized feasibility SOP that defines:

• Responsibilities of feasibility managers, CRAs, and medical reviewers
• Timing of feasibility (pre-IRB, pre-contract)
• Use of digital platforms and validation of e-questionnaires
• Criteria for scoring and risk ranking of sites
• Filing of completed questionnaires in eTMF

The SOP should also include annexures for therapeutic-specific feasibility checklists (e.g., oncology, CNS, vaccines) and region-specific adaptations (e.g., India, China, EU).

Governance committees should oversee feasibility quality by conducting:

• Spot audits of feasibility responses
• Review of enrollment accuracy versus feasibility predictions
• Corrective Action Plans (CAPA) for overestimated sites

Data Integrity and Electronic Feasibility Tools

When using digital platforms, the feasibility process must maintain data integrity standards in line with 21 CFR Part 11 and Annex 11. This includes:

• Audit trails for each change in survey response
• Unique user access for PIs and staff completing the forms
• Electronic signature certification and locking of final entries
• Data backup and disaster recovery plans for e-feasibility tools

For example, if a feasibility platform allows sites to revise their estimated enrollment, the system must log who made the change, when, and why—ensuring full traceability.

Cross-Verification with Source Systems

Feasibility responses must be cross-verified with:

• Clinical Trial Management Systems (CTMS): Prior performance data
• eTMF: GCP training records, signed PI forms
• Public registries: Recruitment metrics from prior trials

This prevents sites from overstating capacity or infrastructure. Some sponsors use feasibility scoring dashboards that auto-rank sites based on enrollment history, deviation rates, and startup timelines—integrated with CTMS and analytics tools.

Regulatory Expectations by Region

Global feasibility assessments must incorporate branching logic or country-specific forms to meet these requirements.

Checklist for Regulatory-Compliant Feasibility

• Completed and signed questionnaire by PI or designee
• Supporting documents for patient estimates and equipment
• GCP certification and CVs reviewed
• Feasibility scoring or risk ranking documented
• SOP version used is up to date and applied consistently
• All documents filed in audit-ready location (eTMF)

Conclusion

Feasibility assessments are not just an operational exercise—they are a regulatory obligation. Sponsors and CROs must ensure their feasibility process is governed by SOPs, aligned with global regulations, and fully documented. Leveraging digital tools, cross-verifying with historical data, and training teams in compliance best practices is essential. With regulatory inspections becoming more rigorous, proper feasibility assessments reduce trial risk, improve start-up timelines, and enhance overall study quality.

How to Evaluate Principal Investigator Experience in Feasibility Questionnaires

Why PI Experience Is Critical to Trial Success

The success of any clinical trial relies significantly on the capabilities of the Principal Investigator (PI). A well-qualified PI ensures proper protocol execution, adherence to Good Clinical Practice (GCP), efficient patient recruitment, and timely data entry. As such, assessing PI experience during the feasibility process is a regulatory and operational necessity. Regulatory authorities like the FDA, EMA, and PMDA emphasize robust PI qualification checks during inspections and sponsor audits.

Feasibility questionnaires are a primary tool for gathering critical information on PI qualifications, experience, and history. If designed correctly, they provide insights into whether a site has the leadership and clinical expertise to conduct the study. Poorly evaluated PIs can lead to protocol deviations, delayed timelines, and even inspection findings.

This article explores the key elements to assess PI experience through feasibility questionnaires, including document review, scoring methods, red flags, and regulatory alignment.

Core Domains to Evaluate PI Experience

A comprehensive feasibility questionnaire should assess multiple dimensions of a PI’s capability:

• Clinical Trial Experience: Number and type of trials conducted (Phase I–IV)
• Therapeutic Area Specialization: Alignment with the protocol indication
• Regulatory History: Inspections, 483 observations, or GCP violations
• Training Credentials: GCP certifications and investigator training logs
• Site Oversight Capacity: Number of trials currently managed

Example questions in a feasibility survey might include:

Document Verification: Going Beyond the Survey

Questionnaire responses alone are not sufficient. Sponsors must request and verify supporting documentation:

• Signed and dated PI CV (within past 2 years)
• GCP certification (ICH E6-compliant, dated within past 2 years)
• Training logs for protocol-specific modules
• Documentation of PI delegation logs from past trials
• Inspection reports or audit summaries (if available)

These documents must be reviewed, archived in the eTMF, and aligned with feasibility questionnaire answers. Discrepancies—such as overstated experience or outdated GCP certificates—should be flagged for clarification before site selection.

For cross-validation, sponsors can refer to clinical trial registries such as ANZCTR to review PIs listed in past studies and compare enrollment timelines and completion status.

Scoring Systems for PI Evaluation

Many sponsors and CROs use scoring systems to quantify PI suitability during the feasibility phase. These scores are based on multiple weighted criteria:

PIs scoring below a predefined threshold (e.g., 70/100) may require additional review or exclusion from site consideration. The scoring model can be automated via CTMS-integrated feasibility platforms.

Red Flags in PI Feasibility Assessments

Watch for these common issues in questionnaire responses or supporting documents:

• PI CV missing or outdated
• More than 5 concurrent studies under PI oversight
• No evidence of protocol-specific training
• Prior inspection with unresolved CAPA
• Enrollment performance not aligned with feasibility estimates

Such red flags should trigger a follow-up interview or teleconference with the site to clarify discrepancies. Regulatory inspectors frequently review these inconsistencies when auditing site selection processes.

Case Study: Protocol Deviations Linked to Inadequate PI Oversight

In a Phase II oncology study, one investigator site experienced 14 protocol deviations within 3 months. Upon review, the feasibility questionnaire listed the PI as experienced, but later it was found that the PI had not attended protocol training and was concurrently managing 7 studies. FDA inspection identified this oversight as a major finding. The sponsor was required to implement new SOPs for PI qualification and conduct a full re-training across all sites.

Regulatory Expectations for PI Evaluation

According to ICH E6(R2), sponsors are required to:

• Evaluate PI qualifications and capability to oversee the trial (Section 5.6)
• Maintain up-to-date records of PI experience, CV, and training (Section 8.2)
• Ensure proper supervision of site staff and trial conduct (Section 4.2)

The FDA’s Bioresearch Monitoring Program also audits how PI qualifications were verified during feasibility and whether their involvement was adequately documented in the TMF.

Best Practices for PI Evaluation Through Questionnaires

• Customize PI sections in feasibility surveys based on protocol complexity
• Use weighted scoring systems for objective evaluation
• Digitally link PI questionnaire responses to their training and inspection history
• Require e-signatures on PI forms to ensure accountability
• Update PI evaluations at study milestones (e.g., mid-recruitment checkpoint)

Conclusion

Evaluating the Principal Investigator’s experience and qualifications is a cornerstone of effective clinical trial feasibility planning. Through well-designed feasibility questionnaires, sponsors can screen for both technical and regulatory competence, minimize risks of protocol violations, and improve trial outcomes. By implementing structured, compliant, and validated PI evaluation frameworks, sponsors not only meet regulatory expectations but also strengthen the foundation for high-quality trial execution.

Adapting Feasibility Assessments for Regional Variations in Global Trials

Why Regional Adaptation in Feasibility Planning Matters

In today’s globally conducted clinical trials, one of the most critical success factors is effective site feasibility planning across diverse geographic regions. From Asia to Europe, Africa to Latin America, clinical sites operate under different regulatory frameworks, healthcare infrastructures, ethics committee procedures, and cultural norms. Applying a uniform feasibility questionnaire across all these regions without localization can lead to inaccurate data, regulatory non-compliance, and delayed trial startup.

To ensure successful study conduct, sponsors and CROs must adapt feasibility tools to reflect local regulatory requirements, operational capacities, and regional experience levels. Regional feasibility variations are not just operational considerations—they are essential to risk-based site selection and inspection readiness.

This article provides a comprehensive guide to tailoring feasibility questionnaires for global studies, explores regulatory expectations by region, and includes real-world strategies for managing geographic variations in feasibility planning.

Common Regional Differences Impacting Feasibility

Several regional characteristics directly affect site feasibility and must be reflected in the questionnaire design:

• IRB/EC Approval Timelines: May vary from 2 weeks (USA) to 3 months (India or Brazil)
• Import Licensing Requirements: Some countries require additional import permits for IP or lab kits
• Language and Documentation: PI CVs, ICFs, and study materials may need translation into local languages
• Regulatory Authority Involvement: Direct regulatory review of protocols may be required (e.g., PMDA in Japan)
• Patient Accessibility: Urban vs. rural site logistics and transportation infrastructure differ

For example, a feasibility questionnaire that asks, “How soon can your site receive ethics committee approval?” must include region-specific dropdowns or logic based on actual country trends and prior experience.

Sample Regional Feasibility Question Adaptations

Here’s how the same feasibility question may need to be adapted for different countries:

These variations not only enhance data quality but also reduce the risk of misinterpreted questions or inconsistent responses from international sites.

Localization of Feasibility Platforms and Tools

Modern feasibility platforms must support multi-language functionality, regional branching logic, and document uploads in country-specific formats. Key features to include:

• Language toggles for questionnaire interface (English, French, Japanese, Spanish, etc.)
• Region-based validation rules (e.g., local license numbers, ethics committee codes)
• Country-specific document upload fields (e.g., PI CV formats, EC letters)
• Integration with country trial registries (e.g., NIHR UK, CTRI India)

Example: In Latin America, sites often need to submit Ministry of Health letters with feasibility responses, requiring fields for “MOH submission date” and “expected response timeline.”

Global Feasibility SOP Considerations

Sponsors should develop a master Feasibility SOP with regional appendices covering:

• Region-specific timelines for IRB and regulatory approvals
• Translation and localization requirements
• Import/export license documentation
• Currency and budget feasibility data for contracts

For instance, the SOP might specify that feasibility questionnaires for trials in China must collect information about the Human Genetic Resources Administration (HGRA) review timelines and documentation practices.

Regulatory Expectations in Regional Feasibility Planning

Health authorities expect feasibility assessments to be aligned with their regional requirements. Below is a summary of key regulatory considerations by region:

Failure to collect region-specific feasibility information can lead to approval delays, protocol amendments, and regulatory non-compliance.

Real-World Case: Regionally Customized Feasibility Accelerates Start-Up

In a global oncology trial involving 75 sites across 12 countries, the sponsor used a region-specific feasibility questionnaire approach. For each country, regulatory, linguistic, and operational fields were customized. This allowed early identification of sites with IRB constraints in Latin America and licensing issues in Southeast Asia. Results:

• ❯ Site activation timelines reduced by 35%
• ❯ Protocol amendments reduced by 20%
• ❯ Improved audit outcomes due to transparent, region-specific feasibility documentation

Data from regional registries such as ClinicalTrials.gov and EU Clinical Trials Register was used to cross-validate site history and performance by geography.

Challenges in Managing Regional Feasibility Variations

Despite its benefits, regional feasibility planning presents challenges:

• Increased complexity in questionnaire management and updates
• Greater need for local expertise to validate regulatory processes
• Difficulty harmonizing data for global dashboards
• Cost and time to localize content and ensure translation accuracy

However, these can be mitigated by engaging local affiliates, training global teams on regional nuances, and leveraging centralized feasibility platforms with region-specific modules.

Best Practices for Regional Feasibility Management

• Develop global core templates with regional add-on modules
• Engage local CROs or site managers to review feasibility content
• Use digital platforms that support branching logic and localization
• Maintain a global feasibility SOP with regional annexures
• Integrate regional performance benchmarks into site selection scoring

Conclusion

Global clinical trials require more than centralized feasibility—it demands regional sensitivity and adaptation. Sponsors who proactively tailor feasibility tools to reflect country-specific timelines, languages, regulations, and healthcare structures will see faster startup, fewer protocol deviations, and smoother inspections. By embedding regional logic into digital platforms and governance SOPs, feasibility planning becomes both globally consistent and locally accurate—ensuring operational success and regulatory compliance.

How to Validate Feasibility Questionnaire Responses in Clinical Trials

The Importance of Validating Feasibility Data

Feasibility questionnaires play a critical role in determining whether a clinical trial site is suitable for participation. However, these tools are only as good as the accuracy of the responses they generate. Self-reported data—if unverified—can lead to unrealistic enrollment projections, infrastructure mismatches, and serious regulatory non-compliance during inspections.

According to ICH E6(R2) and GCP guidelines, sponsors must implement a risk-based approach to trial planning, which includes verification of feasibility assessments. The FDA, EMA, and other global authorities expect documented evidence supporting site claims about patient access, PI experience, prior performance, and infrastructure readiness.

This article provides a step-by-step guide on how to validate feasibility questionnaire responses using cross-verification methods, documentation, risk scoring, and regulatory best practices. Real-world case examples and recommended tools are included.

What Needs Validation in Feasibility Responses?

The following aspects of a typical feasibility questionnaire require validation:

• Patient population estimates
• Investigator clinical trial experience
• Site infrastructure and equipment availability
• Ethics committee and regulatory approval timelines
• Past performance metrics (e.g., enrollment rates, deviation frequency)

These elements are often misreported due to over-optimism, human error, or poor recordkeeping. Therefore, a structured validation process is essential.

Methods for Cross-Validation of Responses

Multiple techniques are used to cross-check the authenticity of feasibility responses:

1. Use of Internal Databases (CTMS, EDC)

Sponsors can retrieve historical trial performance from CTMS to compare with the current feasibility response. For instance, if a site claims it can enroll 60 patients in 6 months, but prior CTMS data shows 20 patients in 12 months for a similar study, this claim warrants further review.

2. Reference to External Registries

Public registries like ISRCTN and ClinicalTrials.gov allow sponsors to validate investigator participation in previous studies and enrollment timelines. Sponsors can match PI names, protocol IDs, and trial dates.

3. Request for Supporting Documents

Sites should provide de-identified hospital records, patient logs, or EHR data to support population claims. For infrastructure, calibration certificates, equipment photos, and maintenance logs should be reviewed.

4. Follow-Up Interviews or Site Televisits

If discrepancies arise, schedule virtual or onsite meetings with the PI or study coordinator to clarify inconsistencies and gather more accurate estimates.

Feasibility Response Verification Table Example

Red Flags That Indicate Validation Is Required

During feasibility review, the following red flags should trigger further scrutiny:

• Patient recruitment claims 2–3x higher than historical benchmarks
• Incomplete PI CV or GCP certification over 3 years old
• Missing documentation for critical equipment (e.g., -80°C freezers, ECG machines)
• Overly short startup timelines without justification
• Sites with previous high deviation rates claiming full protocol compliance

Each red flag should be documented, followed up, and closed before site activation.

Scoring and Risk Categorization of Responses

Validation can be combined with feasibility scoring models to assign a risk category to each site:

Sites categorized as high risk may require additional support or may be excluded from study participation, depending on trial timelines and resource constraints.

Audit Trail and Documentation Requirements

All validation steps must be auditable and retained in the Trial Master File (TMF) or eTMF. Essential records include:

• Annotated questionnaires with reviewer comments
• Emails or notes from follow-up discussions
• Screenshots or documents verifying responses
• Final approval or decision logs by the feasibility committee

This ensures compliance with FDA 21 CFR Part 11 and EMA inspection expectations. Sponsors may also use feasibility-specific document templates for review and version control.

Common Pitfalls in the Validation Process

• Relying solely on site self-assessment without supporting evidence
• Not checking for updated documents like GCP certificates and calibration logs
• Skipping validation due to tight startup timelines
• No SOP or standardized form for feasibility review

To avoid these issues, sponsors should maintain a dedicated Feasibility Review SOP that outlines timelines, reviewer responsibilities, documentation standards, and escalation criteria.

Tools to Support Feasibility Response Validation

• CTMS: For prior site performance records
• eTMF: For document version control and audit trail
• Feasibility Platforms: Veeva Study Startup, Clario, or TrialHub
• Registry Databases: ISRCTN, ClinicalTrials.gov, EU Trials Register
• Dashboards: Power BI or Tableau for response scoring and risk tracking

Conclusion

Validating feasibility questionnaire responses is a critical part of risk-based site selection and trial planning. Relying on unverified data can lead to poor site performance, regulatory findings, and budget overruns. By implementing structured validation workflows, cross-checking with internal and public databases, documenting all review activities, and integrating risk scoring, sponsors and CROs can ensure high data integrity and regulatory compliance. In today’s complex trial landscape, validated feasibility is not just best practice—it’s a regulatory necessity.

How AI-Based Feasibility Tools Are Transforming Site Selection

Introduction: The Limitations of Traditional Feasibility Methods

Clinical trial site selection has traditionally relied on manual feasibility questionnaires, investigator self-reporting, and subjective decision-making by sponsor teams. These legacy methods are often inconsistent, time-consuming, and vulnerable to bias. They fail to leverage the enormous amount of historical and real-time data now available in clinical trial systems, EHRs, and public registries.

As trials grow more complex and global, sponsors need more accurate, data-driven methods to select sites that will meet recruitment targets, adhere to protocols, and pass regulatory scrutiny. Enter artificial intelligence (AI): advanced algorithms capable of analyzing vast datasets to predict which sites are most likely to perform. AI-based feasibility tools are transforming the way sponsors plan, score, and validate site selection decisions.

This article examines how AI is being applied to feasibility in clinical trials, the core functionalities of AI-driven tools, benefits for sponsors and CROs, regulatory considerations, and case studies of successful implementation.

What Are AI-Based Feasibility Tools?

AI-based feasibility tools are platforms or modules that use machine learning algorithms to analyze structured and unstructured data sources to evaluate site capabilities. These tools help predict:

• Likelihood of patient recruitment success
• Protocol deviation risk
• Startup speed and regulatory approval timelines
• Data quality and eCRF completion compliance

Some tools also integrate natural language processing (NLP) to scan free-text site responses, investigator CVs, or prior inspection reports to uncover potential red flags.

Example vendors and tools include:

• TrialHub: Combines historical site performance with real-world epidemiological data
• SiteIQ (IQVIA): Uses predictive modeling based on global site benchmarking
• Antidote Match: Uses AI to match patients to studies and model site potential

Data Sources Used in AI Feasibility Models

AI-based feasibility platforms aggregate data from numerous sources to fuel their predictive engines:

For example, a site may self-report a capacity to recruit 60 patients for a metabolic trial. An AI tool might access EHR data, recognize only 20 qualified patients in the database, and flag this discrepancy for manual review—improving selection accuracy.

Publicly available registries such as Canada’s Clinical Trials Database can also be integrated for validation purposes.

Core Functionalities of AI-Based Site Selection Platforms

AI feasibility tools typically include several key modules:

• Predictive Enrollment Modeling: Analyzes patient population and prior enrollment speed
• Feasibility Scoring Engines: Generates composite scores based on predefined KPIs
• Automated Questionnaire Review: Uses NLP to detect inconsistencies or gaps
• Risk Ranking: Categorizes sites by low/medium/high risk for deviations or noncompliance
• Dynamic Dashboards: Visualize site performance, regulatory readiness, and projected ROI

These platforms often integrate into CTMS and eTMF systems, allowing sponsors to move directly from feasibility to activation workflows.

Benefits of Using AI in Feasibility Planning

Adopting AI-based feasibility solutions brings measurable improvements:

• Reduced site activation time by 20–40%
• Lower protocol deviation rates
• Better enrollment forecasting accuracy
• Centralized, audit-ready documentation of decisions
• Objective and reproducible site selection process

In addition, AI tools reduce the reliance on subjective site self-assessments, which have historically led to overestimated recruitment capabilities and inconsistent site performance.

Regulatory Considerations and Compliance

While AI tools provide operational advantages, they must align with regulatory expectations for site selection documentation. Regulatory guidelines from the FDA, EMA, and ICH GCP specify:

• Sponsors must document how and why a site was selected
• Tools used must be validated and audit-ready
• Site scoring models should be reproducible and transparent
• Electronic records must comply with 21 CFR Part 11 and Annex 11

Sponsors using AI should retain documentation of algorithm logic, input data sources, risk scores, and any manual overrides. These materials must be made available during audits and inspections.

Challenges and Limitations

Despite the advantages, several challenges must be addressed:

• Data privacy concerns, especially in EHR integrations (GDPR compliance)
• Bias in historical data used to train AI models
• Limited AI adoption in certain regulatory environments
• Cost of implementation and platform validation
• Need for human oversight to interpret AI-generated outputs

These can be mitigated through hybrid models combining AI recommendations with expert review, robust SOPs for AI-assisted feasibility, and use of explainable AI models with transparent logic.

Case Study: Oncology Trial Using AI Feasibility Scoring

In a recent global Phase III oncology trial, the sponsor deployed an AI feasibility platform across 120 potential sites. Key outcomes:

• ➤ 32% reduction in average site startup time
• ➤ 18% increase in patient enrollment rates
• ➤ 25% fewer protocol deviations from selected sites
• ➤ All site selection decisions were documented and passed regulatory audit

The platform integrated CTMS and external registry data, flagged 14 sites as high-risk, and prioritized 60 low-risk, high-potential sites. This enabled resource optimization and stronger trial performance metrics.

Best Practices for Implementing AI-Based Feasibility Tools

• Start with a pilot study to validate tool accuracy and user acceptance
• Document all model assumptions, logic, and scoring weights
• Train feasibility and QA teams in interpreting AI outputs
• Ensure data security, consent, and privacy compliance
• Create audit trail reports for all AI-generated recommendations

Conclusion

AI is rapidly changing the way feasibility assessments and site selection are conducted in clinical research. By analyzing historical and real-time data, AI tools can predict site performance with higher accuracy, reduce risk, and improve compliance. Sponsors and CROs that embrace AI-powered feasibility tools position themselves to execute faster, more cost-effective, and regulatorily sound trials. As these tools evolve, they will become integral to the digital transformation of global clinical trial operations.